NEW YORK (GenomeWeb News) – Shares in Accelr8 were up 13.17 percent, or $.27, at $2.32 in mid-afternoon trading after the company said it won a US patent that covers devices that use its OptiChem surface chemistry, including those for patient specimen collection and analytical products.
 
Accel8 said U.S. Patent 7,067,194 also covers coating variations not specifically included in prior patents.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.